3 recruiting, 1 active not recruiting, 1 terminated. 2 Phase 1, 2 Phase 2, 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 2 | Active not recruiting 1, Terminated 1 |
| Phase 2 | 2 | Recruiting 2 |
| Phase 3 | 2 | Recruiting 2 |
Follow Advanced Esophageal Adenocarcinoma: new trials by email Literature Review of Advanced Esophageal Adenocarcinoma trials Research Report on Advanced Esophageal Adenocarcinoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Testing Ivonescimab in Combination With Chemotherapy in Advanced or Metastatic Gastric/Gastroesophageal Adenocarcinoma Ivonescimab, FOLFOX regimen, Irinotecan - Metastatic Esophageal Adenocarcinoma, Advanced Esophageal Adenocarcinoma | Phase 2 | Recruiting | UNICANCER | 88 | 2025-11-20 | 2026-04-28 |
| A First-in-human Study of BGB-53038, a Pan-KRAS Inhibitor, Alone or in Combinations in Participants With Advanced or Metastatic Solid Tumors With KRAS Mutations or Amplification BGB-53038, Tislelizumab, Cetuximab - Metastatic Solid Tumors, Advanced Non-squamous Non-small-cell Lung Cancer | Phase 1 | Terminated | BeOne Medicines | 47 | 2024-12-13 | 2026-07-08 |
| Adding Nivolumab to Usual Treatment for People With Advanced Stomach or Esophageal Cancer, PARAMUNE Trial Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging - Advanced Esophageal Adenocarcinoma, Advanced Gastric Adenocarcinoma | Phase 2 / Phase 3 | Recruiting | National Cancer Institute (NCI) | 224 | 2024-06-24 | 2026-10-21 |
| mFOLFIRINOX Versus mFOLFOX With or Without Nivolumab for the Treatment of Advanced, Unresectable, or Metastatic HER2 Negative Esophageal, Gastroesophageal Junction, and Gastric Adenocarcinoma Fluorouracil, Leucovorin Calcium, Oxaliplatin - Advanced Esophageal Adenocarcinoma, Advanced Gastric Adenocarcinoma | Phase 3 | Recruiting | Alliance for Clinical Trials in Oncology | 382 | 2023-01-31 | 2026-10-02 |
| Testing the Addition of the Anti-cancer Viral Therapy Telomelysin™ to Chemoradiation for Patients With Advanced Esophageal Cancer and Are Not Candidates for Surgery Carboplatin, Paclitaxel, Radiation Therapy - Advanced Esophageal Adenocarcinoma, Advanced Gastroesophageal Junction Adenocarcinoma | Phase 1 | Active not recruiting | NRG Oncology | 16 | 2021-12-02 | 2026-10-01 |
Adenocarcinoma Of Esophagus (3) · Adenocarcinoma (1) · Carcinoma, Squamous Cell (1) · Neoplasm Metastasis (1) · Neoplasms (1) · Neoplasms, Squamous Cell (1)
Carcinoma (2) · Neoplasms by Histologic Type (2) · Neoplasms, Glandular and Epithelial (2) · Neoplasms (1) · Neoplastic Processes (1) · Pathologic Processes (1) · Pathological Conditions, Signs and Symptoms (1)
Paclitaxel (3) · Fluorouracil (2) · Irinotecan (2) · Leucovorin (2) · Magnetic Resonance Spectroscopy (2) · Nivolumab (2) · Oxaliplatin (2) · Taxes (2) · Carboplatin (1) · Cetuximab (1) · Folfox protocol (1) · Radiation (1) · Radiotherapy (1) · Ramucirumab (1) · Specimen Handling (1)
Alliance for Clinical Trials in Oncology (1) · BeOne Medicines (1) · NRG Oncology (1) · National Cancer Institute (NCI) (1) · UNICANCER (1)
United States (4) · Australia (1) · China (1) · France (1) · New Zealand (1) · Puerto Rico (1) · South Korea (1)
Anwaar Saeed (1) · Geoffrey Y Ku (1)
2025 (1), U10CA180868 (1), U10CA180888 (1)